Big week for prostate cancer ( especially for PSMA enthusiasts like us!), with the phase III VISION trial heading the plenary session at the ASCO Annual Meeting. VISION is the long-awaited pivotal randomised trial of Lu-PSMA vs standard of care for men with progressive mCRPC following chemo +/- AR pathway inhibitors. Lots of stuff to dive into, even as we await the NEJM paper. We scrutinise the control arm and dive deep into teh issue of imaging and patient selection.Regular hosts Professor Declan Murphy and Dr Renu Eapen are joined by some of our experienced Lu-PSMA specialists at Peter Mac, Professor Michael Hofman and Associate Professor Arun Azad. Links;Dr Mike Morris TwitterUroToday report from Dr Chris Wallis